Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II prospective, randomized, standard treatment–parallel controlled study will evaluate XS411 for Primary Parkinson's Disease

Next Previous
Trial Profile

A Phase II prospective, randomized, standard treatment–parallel controlled study will evaluate XS411 for Primary Parkinson's Disease

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 20 Apr 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs XS 411 (Primary)
  • Indications Parkinson's disease
  • Focus Registrational; Therapeutic Use

Most Recent Events

  • 20 Apr 2026 New trial record
  • 14 Apr 2026 According to XellSmart Biopharmaceutical media release, this Phase II clinical trial, approved by China's National Medical Products Administration (NMPA) and hospital ethics committees.
  • 14 Apr 2026 According to XellSmart Biopharmaceutical media release, the advance into Phase II trial in less than one year from 2025

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top